Navigation Links
Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite
Date:6/30/2009

rts more than 600 hospitals, health systems, regional health information organizations (RHIOs) and health information exchanges (HIEs) across North America and Europe.

Founded in 2002 and headquartered in Scottsdale, AZ, Carefx can be reached at (480) 833-5010 or by email at info (at) carefx (dot) com.

About Virginia Mason Medical Center
Virginia Mason Medical Center, founded in 1920, is a non-profit comprehensive regional health-care system in Seattle that combines a primary and specialty care group practice of more than 480 physicians with a 336-bed acute-care hospital. Virginia Mason operates a network of clinics throughout the Puget Sound area; manages Bailey-Boushay House, a nursing residence and chronic care management program for people living with HIV and AIDS; and operates Benaroya Research Institute at Virginia Mason, internationally recognized in autoimmune disease research. Virginia Mason is known for applying the Toyota Production System to health care to improve quality and patient safety. For more information, visit VirginiaMason.org.

MEDIA CONTACT:
Christopher Capot
KNB Communications
212-505-2441, 203-379-8019 (mobile)

# # #

Read the full story at http://www.prweb.com/releases/Carefx/Virginia_Mason/prweb2590894.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Virginia Tech Report Has National Importance
2. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
3. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
4. Virginia Techs Raving First Year Results Lead to Additional High-Tech Antimicrobial Defense from SportCoatings(TM)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
7. Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products
8. The Virginia G. Piper Charitable Trust and Flinn Foundation launch
9. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
10. States Largest Medicaid Managed Care Plan Offering Training to Combat West Virginia Obesity Epidemic
11. Virginia Attorney General Addresses Drunk Driving and Underage Drinking in New Radio Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite
Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite
(Date:5/16/2012)... issue of BioResearch Open Access , a ... today by Mary Ann Liebert, Inc., publishers. The ... broad range of scientific topics including but not ... and biomaterials, regenerative medicine, stem cells, gene therapy, ... The first issue is available on the ...
(Date:5/16/2012)... (HealthDay News) -- Heart palpitations and high blood pressure ... disorder called atrial fibrillation, a new study reports. ... stroke and death. It was already known that high ... but, according to the researchers, this is the first ... palpitations, which are commonly felt as a rapid or ...
(Date:5/16/2012)... myeloma patients are better equipped to halt progression of ... following a stem cell transplant, according to a study ... Science University Knight Cancer Institute. , The study, published ... found a 63 percent reduction in the risk of ... patients that were treated with lenalidomide maintenance therapy. , ...
(Date:5/15/2012)... Carina Storrs HealthDay Reporter , , TUESDAY, May ... to begin in London this summer, a new study ... an important public health message: Reducing air pollution levels ... Four years ago, an international team of ... the 2008 Olympics, to see what health effects those ...
(Date:5/15/2012)... (HealthDay News) -- Researchers have identified gene variants ... they say their findings could help identify patients ... The researchers, from the University of California-Los Angeles, ... develop new therapies. Parkinson,s disease is a ... rigidity. The researchers followed 233 patients for ...
Breaking Medicine News(10 mins):Health News:Premier issue of BioResearch Open Access launched by Mary Ann Liebert Inc. publishers 2Health News:Palpitations May Signal Future Heart Rhythm Problem 2Health News:Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 3Health News:Genes Might Be Key to Parkinson's Spread 2
... the third phase of clinical trail conducted by researchers at ... weekly dose of erythropoietin //(EPO) is a very effective treatment ... ,EPO is a natural hormone that stimulates production ... cell (RBC) transfusions in these children. This is the ...
... in New York City has discovered that chronic pain occurs ... his colleagues were studying chronic pain at the molecular and ... occurs and the neurons becomes excited and begin to send ... when the stimulus is removed the nerves become dormant and ...
... exchange agreement with an Israeli company to introduce its ... technology enabled patients to be monitored anywhere and at ... telephones, Heartline Managing Director Dr Selva Annamalai told reporters ... doctor, 24 hours a day from anywhere, who could ...
... condition, chronic widespread pain is often difficult to ... depression and poor sleep.// ,A link between ... FM like symptoms after treatment with cytokine interleukin ... contradictory results. A new study published in the ...
... Cambodia in the Aids prevention initiatives have been applauded, ... of condoms.// ,Professor K. Satkunantham, the director of ... 100 per cent condom use programmes in Thailand and ... ,In the 25 years of the existence ...
... French teenage girl was admitted appearing unsteady and mentally sluggish ... doctors. // ,In addition it was found that the ... were puzzled because there appeared to be no family history ... in this week's New England Journal of Medicine. ...
Other Medicine News:Health News:EPO Effective For Cancer Patients Suffering From Anemia 2Health News:Insufficent Anti-inflammatoy Proteins Leads to Chronic Pain 2Health News:Teens High on Mothballs 2
(Date:5/15/2012)... -- PLC Systems Inc. (OTCBB: PLCSF), a company focused ... results for the three-month period ended March 31, ... operations, since PLC completed the sale of its ... the first quarter of 2011.  Results from the ... all periods presented. First quarter 2012 ...
(Date:5/15/2012)... 15, 2012 BiO2 Medical, Inc. a ... in San Antonio, Texas, and R&D and manufacturing ... has received CE Mark approval for the Angel™ ... permanently attached to a central venous catheter (CVC) ... in critically ill patients. This novel IVC filter/CVC ...
(Date:5/15/2012)... May 15, 2012  Boston Scientific Corporation ... the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium ... treating de novo coronary artery ... PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System ...  The trial reported one-year clinical and six-month ...
Breaking Medicine Technology:PLC Systems Reports First Quarter 2012 Results 2PLC Systems Reports First Quarter 2012 Results 3PLC Systems Reports First Quarter 2012 Results 4PLC Systems Reports First Quarter 2012 Results 5PLC Systems Reports First Quarter 2012 Results 6One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 1Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 1Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 1Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 2Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 3Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 5Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 6Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 7Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 8Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 9Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 10Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 11Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 12Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 13Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 14Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 15Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 16Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 17
... Presented at International Conference on Malignant ... Shows Dose Dependent Single Agent Activity, BETHESDA, ... biopharmaceutical company developing novel, proprietary antibodies,for the treatment ... update of an ongoing phase 1 clinical trial ...
... Discuss Clinical, Financial ... DUBLIN, Ohio, June 4 In a move that ... of,hospital-acquired infections (HAIs), Cardinal Health announced today that,it will ... will focus on the leadership and operational issues that ...
Other Medicine Technology:Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 2Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 3Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 4Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 5Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 2Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 3Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 4
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
Medicine Products: